DAA treatment
PreclinicalSmall molecule
DAA treatment is one of 7 small molecule programs targeting Cryoglobulinemia. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Cryoglobulinemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Gazyva
RochePhase 2
Benlysta
GGlaxo Dba Glaxosmithkline
Phase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 1
DAA treatment
HHospices Civils de Lyon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DAA treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospices Civils de Lyon